Taipei's Bora wants in on the CDMO game as report shows plenty of room for industry growth
Taipei’s Bora Pharmaceuticals has linked up with Taishin Healthcare to invest about $108 million into CDMOs and CROs in response to a booming business environment for both industries.
The two companies plan to enter the macromolecular, and cell and gene therapy manufacturing spaces, and strengthen competitiveness while bolstering Taiwan’s CDMO market. According to a report from Hartford, CT-based research group Global Information, the global CDMO market was valued at $160.1 billion in 2020 and could grow to as much as $242.64 billion by 2026. There are five CDMOs in the world that have revenue above $500 million, while 75% of the field takes in less than $50 million in revenue, the report says.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.